Tracon shares slammed by PhII bust in brain cancer study; Visterra yanks its IPO in back-to-back duds
• Shares of San Diego-based Tracon $TCON got slammed this morning after investigators said that the Phase II NCI study of TRC105 in recurrent glioblastoma failed. The study was designed to detect if a combination of TRC105 and Avastin could substantially improve the progression-free survival rate of patients over what would be expected for Avastin alone. That didn’t work. The stock was down 21% in early trading Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.